Myeloma Today - Spring 2024

VOLUME 24 NUMBER 2 | SPRING 2024

A publication of the International Myeloma Foundation

Two New FDA Approvals are Here! Abecma® and Carvykti® CAR T-cell therapies now available earlier in the myeloma journey

ALSO IN THIS EDITION: New data from DREAMM-7 and DREAMM-8 studies Interim analyses from clinical trials of combination therapies with Blenrep® (belantamab mafodotin-blmf), an antibody-drug conjugate, demonstrate positive results in progression-free survival This edition of Myeloma Today is supported by Bristol Myers Squibb • GSK • Johnson & Johnson • Karyopharm Therapeutics • Pfizer • Takeda Oncology

Turn static files into dynamic content formats.

Create a flipbook

Myeloma Today - Spring 2024

Published on Apr 15, 2024

International Myeloma Foundation

The spring edition of Myeloma Today, is filled with promising developments in the field of myeloma. Here are some highlights: Two New FDA Approvals: Abecma® and Carvykti® CAR T-cell therapies have been approved for earlier use in the myeloma journey, expanding treatment options and improving patient outcomes. Read about interim analyses from clinical trials of combination therapies with Blenrep® demonstrate positive results in progression-free survival. Learn about the newly granted accelerated approval by the FDA for Elrexfio, a BCMA-directed CD3 T-cell engager, for the treatment of relapsed or refractory myeloma. Also, this issue spotlights IMF's global campaign, Myeloma ACTION Month, which was a huge success as it reached over 52 million people in 36 countries. Finally, find out how you can get involved in advocating for increased cancer research funding and making a difference in the lives of myeloma patients.

Issuu converts static files into:

and more. Sign up and create your flipbook.

Myeloma Today - Spring 2024 by International Myeloma Foundation - Issuu